Cargando…

RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation

Oestrogen receptor ɑ (ERɑ) is overexpressed in two‐thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ‐positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhenhua, Zhang, Jinghang, Xu, Juntao, Yang, Huijie, Li, Xin, Hou, Yingxiang, Zhao, Yan, Xue, Min, Wang, Beibei, Yu, Na, Yu, Sifan, Niu, Gang, Wu, Gaosong, Li, Xiumin, Wang, Hui, Zhu, Jian, Zhuang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111850/
https://www.ncbi.nlm.nih.gov/pubmed/29974997
http://dx.doi.org/10.1111/jcmm.13694
_version_ 1783350746030276608
author Liu, Zhenhua
Zhang, Jinghang
Xu, Juntao
Yang, Huijie
Li, Xin
Hou, Yingxiang
Zhao, Yan
Xue, Min
Wang, Beibei
Yu, Na
Yu, Sifan
Niu, Gang
Wu, Gaosong
Li, Xiumin
Wang, Hui
Zhu, Jian
Zhuang, Ting
author_facet Liu, Zhenhua
Zhang, Jinghang
Xu, Juntao
Yang, Huijie
Li, Xin
Hou, Yingxiang
Zhao, Yan
Xue, Min
Wang, Beibei
Yu, Na
Yu, Sifan
Niu, Gang
Wu, Gaosong
Li, Xiumin
Wang, Hui
Zhu, Jian
Zhuang, Ting
author_sort Liu, Zhenhua
collection PubMed
description Oestrogen receptor ɑ (ERɑ) is overexpressed in two‐thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ‐positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further understanding of the underlying mechanisms ERɑ signalling is critical in dealing with endocrine resistance in breast cancer patients. MCF‐7 and T47D breast cancer cell lines are used to carry out the molecular biological experiments. Western blot is used to assess the relative protein level of ERɑ, RNF168 and actin. Real‐time PCR is used the measure the relative ERɑ‐related gene mRNA level. Luciferase assay is used to measure the relative ERɑ signalling activity. Chromatin immunoprecipitation is used to measure the RNF168 binding affinity to ERɑ promoter regions. WST assay and flow cytometry are used to measure the cell proliferation capacity. We use Student's t test and one‐way ANOVA test for statistical data analysis. Here, we report an important role in ERɑ‐positive breast cancer cells for RNF168 protein in supporting cell proliferation by driving the transcription of ERɑ. RNF168 is highly expressed in breast cancer samples, compared with normal breast tissue. In patients with breast cancer, RNF168 expression level is correlated with poor endocrine treatment outcome. Depletion of RNF168 causes decreased cell proliferation in MCF‐7 and T47D cells. Besides, depletion RNF168 reduced mRNA level of ERɑ and its target genes, such as PS2 and GREB1. Chromatin immunoprecipitation revealed that ERɑ transcription is associated with RNF168 recruitment to ERɑ promoter region, suggesting that transcriptional regulation is one mechanism by which RNF168 regulates ERɑ mRNA level and ERɑ signalling in breast cancer cells. RNF168 is required for ERɑ‐positive breast cancer cell proliferation and facilitate ERɑ signalling activity possibly through promoting transcription of ERɑ.
format Online
Article
Text
id pubmed-6111850
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61118502018-09-01 RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation Liu, Zhenhua Zhang, Jinghang Xu, Juntao Yang, Huijie Li, Xin Hou, Yingxiang Zhao, Yan Xue, Min Wang, Beibei Yu, Na Yu, Sifan Niu, Gang Wu, Gaosong Li, Xiumin Wang, Hui Zhu, Jian Zhuang, Ting J Cell Mol Med Original Articles Oestrogen receptor ɑ (ERɑ) is overexpressed in two‐thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ‐positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further understanding of the underlying mechanisms ERɑ signalling is critical in dealing with endocrine resistance in breast cancer patients. MCF‐7 and T47D breast cancer cell lines are used to carry out the molecular biological experiments. Western blot is used to assess the relative protein level of ERɑ, RNF168 and actin. Real‐time PCR is used the measure the relative ERɑ‐related gene mRNA level. Luciferase assay is used to measure the relative ERɑ signalling activity. Chromatin immunoprecipitation is used to measure the RNF168 binding affinity to ERɑ promoter regions. WST assay and flow cytometry are used to measure the cell proliferation capacity. We use Student's t test and one‐way ANOVA test for statistical data analysis. Here, we report an important role in ERɑ‐positive breast cancer cells for RNF168 protein in supporting cell proliferation by driving the transcription of ERɑ. RNF168 is highly expressed in breast cancer samples, compared with normal breast tissue. In patients with breast cancer, RNF168 expression level is correlated with poor endocrine treatment outcome. Depletion of RNF168 causes decreased cell proliferation in MCF‐7 and T47D cells. Besides, depletion RNF168 reduced mRNA level of ERɑ and its target genes, such as PS2 and GREB1. Chromatin immunoprecipitation revealed that ERɑ transcription is associated with RNF168 recruitment to ERɑ promoter region, suggesting that transcriptional regulation is one mechanism by which RNF168 regulates ERɑ mRNA level and ERɑ signalling in breast cancer cells. RNF168 is required for ERɑ‐positive breast cancer cell proliferation and facilitate ERɑ signalling activity possibly through promoting transcription of ERɑ. John Wiley and Sons Inc. 2018-07-05 2018-09 /pmc/articles/PMC6111850/ /pubmed/29974997 http://dx.doi.org/10.1111/jcmm.13694 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Liu, Zhenhua
Zhang, Jinghang
Xu, Juntao
Yang, Huijie
Li, Xin
Hou, Yingxiang
Zhao, Yan
Xue, Min
Wang, Beibei
Yu, Na
Yu, Sifan
Niu, Gang
Wu, Gaosong
Li, Xiumin
Wang, Hui
Zhu, Jian
Zhuang, Ting
RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
title RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
title_full RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
title_fullStr RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
title_full_unstemmed RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
title_short RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
title_sort rnf168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111850/
https://www.ncbi.nlm.nih.gov/pubmed/29974997
http://dx.doi.org/10.1111/jcmm.13694
work_keys_str_mv AT liuzhenhua rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT zhangjinghang rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT xujuntao rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT yanghuijie rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT lixin rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT houyingxiang rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT zhaoyan rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT xuemin rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT wangbeibei rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT yuna rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT yusifan rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT niugang rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT wugaosong rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT lixiumin rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT wanghui rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT zhujian rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation
AT zhuangting rnf168facilitatesoestrogenreceptorɑtranscriptionanddrivesbreastcancerproliferation